Search & Analyze

Mankind Pharma Ltd.

HealthcarePharmaceuticals & Drugs

www.mankindpharma.com BSE: 543904NSE: MANKIND

₹2,217.00BSE2.63%

23 Oct, 4:01 PM

₹2,217.00

₹91.57K Cr

44.83

5.44

12.69%

₹2,280.65

₹2,198.05

₹2,640.30

₹1,909.90

Customise metrics bar

Mankind Pharma Ltd. (MANKIND) share price closed at ₹2,217.00 on the BSE on Friday, October 23, 2026, down by 2.63% from its of ₹2,276.80. In that session MANKIND reached a of 2,280.65 and of 2,198.05. The for the session was 2,219.18. The stands at 2,376.80 and is at 2,306.83. Looking at , the stock ended the session in Downtrend.

Stock Overview

Symbol

MANKIND

₹2,280.65

₹2,276.80

₹2,219.18

₹2,376.80

Price 6.72% below

₹2,306.83

Price 3.89% below

22.94% of range

₹2,198.05₹2,280.65

42.05% of range

₹1,909.90₹2,640.30

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,743.00	34.58	4,18,204.09	0.92	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	8,984.00	81.54	2,38,496.97	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,482.00	80.26	1,70,480.87	0.85	534.00	-9.64%	4,979.00	50.79%	19.27
ZYDUSLIFE ZYDUSLIFE	1,127.85	24.93	1,12,503.47	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,337.00	32.04	1,08,012.30	0.97	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,974.00	97.55	1,06,657.63	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,224.50	36.50	1,02,206.60	0.65	913.20	-31.69%	8,697.80	-1.48%	13.75
Mankind Pharma Ltd. MANKIND	2,217.00	44.83	91,572.10	0.05	574.09	29.12%	4,030.59	12.89%	13.24

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,422.24	2,867.85	3,061.43	3,198.79	3,079.37	3,570.35	3,697.16	3,567.20	3,442.93	4,030.59
Expenses	1,835.94	2,196.29	2,214.24	2,382.80	2,396.18	2,723.58	2,775.83	2,647.77	2,513.05	2,974.40
	586.30	671.56	847.19	815.99	683.19	846.77	921.33	919.43	929.88	1,056.19
	24.20%	23.42%	27.67%	25.51%	22.19%	23.72%	24.92%	25.77%	27.01%	26.20%
	92.15	99.40	109.06	77.00	251.33	79.88	91.87	-33.84	91.13	45.00
Interest	9.17	10.84	7.10	220.93	190.54	170.65	169.68	157.20	141.75	109.98
	99.78	102.69	100.49	187.17	230.87	218.68	221.82	222.60	223.08	225.70
	571.91	661.34	851.23	488.33	515.43	540.49	624.02	509.00	659.17	769.45
	16.61%	18.58%	22.32%	22.62%	16.77%	17.74%	16.64%	18.69%	15.13%	25.39%
	471.24	536.49	653.47	380.23	420.77	438.32	511.51	408.75	554.35	568.06
	11.76	13.39	16.31	9.22	10.20	10.62	12.39	9.90	13.43	13.75

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	8,070.80	9,105.63	10,677.38	12,678.36	14,936.45
	7,781.56	8,749.43	10,260.44	12,207.44	14,277.64
EXPENDITURE :
Increase/Decrease in Stock	-449.59	290.74	-53.67	-183.00	36.12
Raw Material Consumed	2,871.32	2,622.90	3,252.14	3,672.04	4,016.00
Power & Fuel Cost	103.13	108.96	125.16	149.49	183.71
Employee Cost	1,620.59	1,918.47	2,260.60	2,692.37	3,183.90
Other Manufacturing Expenses	160.29	150.57	172.71	216.03	337.05
General and Administration Expenses	655.99	1,000.80	939.49	1,314.02	1,424.20
Selling and Distribution Expenses	708.17	638.11	924.26	1,164.71	1,325.12
Miscellaneous Expenses	121.10	116.96	124.58	161.31	149.16
	5,791.01	6,847.50	7,745.27	9,186.97	10,655.26
Operating Profit (Excl OI)	1,990.55	1,901.93	2,515.17	3,020.47	3,622.38
	196.03	128.57	280.22	536.79	358.79
	2,186.58	2,030.50	2,795.39	3,557.26	3,981.17
Interest	59.80	45.76	34.24	431.95	644.25
PBDT	2,126.77	1,984.73	2,761.15	3,125.31	3,336.92
	166.62	325.92	378.42	621.22	886.18
Profit Before Taxation & Exceptional Items	1,960.15	1,658.81	2,382.73	2,504.09	2,450.74
Exceptional Income / Expenses					-129.75
	1,974.60	1,671.24	2,397.94	2,516.33	2,332.68
Provision for Tax	521.64	361.56	457.15	509.74	394.58
	1,452.96	1,309.68	1,940.79	2,006.59	1,938.10
Extra items				4.53	0.00
Minority Interest	-19.48	-27.82	-28.87	-20.16	-25.17
Consolidated Net Profit	1,433.48	1,281.86	1,912.90	1,990.96	1,912.93
Profit Balance B/F	5,303.51	6,735.19	8,012.20	9,918.83	11,907.32
Appropriations	6,736.98	8,017.05	9,925.10	11,909.79	13,820.25
Equity Dividend %					100.00%
	35.78	32.00	47.75	48.25	46.34
Adjusted EPS	35.78	32.00	47.75	48.25	46.34

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	40.06	40.06	40.06	41.26	41.28
Share Warrants & Outstandings		0.06	23.25	43.67	47.72
Total Reserves	6,115.17	7,395.10	9,299.78	14,247.46	16,211.34
Reserve excluding Revaluation Reserve	6,115.17	7,395.10	9,299.78	14,247.46	16,211.34
	6,155.23	7,435.22	9,363.09	14,332.39	16,300.34
Minority Interest	161.08	188.07	212.70	235.79	260.71
Secured Loans	48.94	23.15	24.87	5,077.83	2,482.65
Unsecured Loans	0.25			448.36	338.58
Deferred Tax Assets / Liabilities	16.33	47.54	8.68	1,704.62	1,515.28
Other Long Term Liabilities	23.14	30.67	30.67	34.03	101.37
Long Term Provisions	80.00	97.89	123.12	155.06	248.65
Total Non-Current Liabilities	168.68	199.24	187.34	7,419.90	4,686.53
Trade Payables	1,076.40	1,008.18	777.06	1,133.40	1,341.33
Other Current Liabilities	472.89	386.05	755.50	1,335.07	3,702.35
Short Term Borrowings	794.59	115.02	151.48	2,513.14	638.92
Short Term Provisions	279.59	353.89	435.69	681.95	824.65
Total Current Liabilities	2,623.46	1,863.14	2,119.73	5,663.56	6,507.25
Total Liabilities	9,108.45	9,685.67	11,882.86	27,651.64	27,754.83
Gross Block	4,246.54	5,233.03	5,909.74	20,916.96	21,376.79
Less: Accumulated Depreciation	663.78	987.75	1,369.79	1,912.48	2,756.34
Net Block	3,582.77	4,245.28	4,539.95	19,004.48	18,620.45
Capital Work in Progress	669.87	493.19	207.10	306.13	654.78
Non Current Investments	235.01	270.95	309.81	351.09	447.87
Long Term Investment	235.01	270.95	309.81	351.09	447.87
Long Term Loans & Advances	163.88	187.54	163.97	293.08	554.72
Other Non Current Assets	13.09	98.51	13.79	189.00	49.91
Total Non-Current Assets	4,701.63	5,357.80	5,314.64	20,663.37	20,800.63
Currents Investments	874.46	1,075.47	2,258.11	1,690.84	1,537.31
Inventories	1,760.24	1,498.46	1,553.46	2,093.71	2,144.48
Sundry Debtors	388.17	576.42	848.28	1,538.34	1,729.51
Cash and Bank	405.94	453.20	708.10	554.50	482.77
Other Current Assets	170.74	64.29	104.10	97.42	100.73
Short Term Loans and Advances	804.29	656.71	1,093.47	1,010.76	956.70
Total Current Assets	4,403.84	4,324.56	6,565.52	6,985.57	6,951.50
Net Current Assets (Including Current Investments)	1,780.37	2,461.42	4,445.79	1,322.01	444.25
Total Assets	9,108.45	9,685.67	11,882.86	27,651.64	27,754.83
Contingent Liabilities	82.57	47.92	89.01	1,019.46	924.77
Total Debt	868.03	162.64	196.04	8,300.47	6,021.78
	153.65	185.61	233.15	346.31	393.72
Adjusted Book Value	153.65	185.61	233.15	346.31	393.72

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	1,974.60	1,671.24	2,399.35	2,524.78	2,332.68
Adjustment	30.81	298.43	212.19	601.79	1,276.52
Changes In working Capital	-586.12	166.73	-17.57	-146.44	104.82
Cash Flow after changes in Working Capital	1,419.29	2,136.40	2,593.97	2,980.13	3,714.02
Cash Flow from Operating Activities	919.78	1,813.30	2,152.44	2,413.38	3,121.29
Cash Flow from Investing Activities	-1,369.14	-1,054.13	-2,081.69	-12,682.95	-196.42
Cash Flow from Financing Activitie	604.62	-739.73	5.27	10,232.56	-2,952.69
Net Cash Inflow / Outflow	155.26	19.44	76.02	-37.01	-27.82
Opening Cash & Cash Equivalents	127.33	283.06	304.82	382.01	403.88
Cash & Cash Equivalent on Amalgamation / Take over / Merger				-9.40
Cash & Cash Equivalent of Subsidiaries under liquidations				66.97
Effect of Foreign Exchange Fluctuations	0.48	2.32	1.17	1.31	15.63
Closing Cash & Cash Equivalent	283.06	304.82	382.01	403.88	391.69

Ratios

Valuation

44.83

5.44

23.40

6.21

49.45

407.39

Profitability

12.69

13.24

7.00

24.25

12.98

Leverage & Liquidity

0.37

1.07

4.62

Returns

0.05

0.54

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	74.87	74.87	72.71	72.70	72.68	72.67	72.66	72.66	72.63	72.62
	21.53	22.27	24.40	24.37	24.53	24.72	24.55	24.66	24.80	24.89
	3.61	2.86	2.90	2.93	2.79	2.61	2.79	2.68	2.57	2.49
	25.13	25.13	27.29	27.30	27.32	27.33	27.34	27.34	27.37	27.38
No. of Shareholders	1,53,450	1,63,854	1,71,281	1,80,597	1,79,549	1,70,347	1,77,539	1,77,606	1,66,715	1,63,770

Mutual Funds Invested(227)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 143 active funds hold 10.96% in Mankind Pharma Ltd., contributing to ₹11.34K Cr of holdings

Fund				As of
SB SBI Large Cap Fund - Growth - Direct PlanLarge Cap Fund	1,019.78	1.95	40,72,930	Sep '26
NI Nippon India Growth Mid Cap Fund - Growth Option - Direct PlanMid Cap Fund	976.48	1.95	39,00,000	Sep '26
HD HDFC Large Cap Fund - Growth - Direct PlanLarge Cap Fund	685.91	1.84	27,39,492	Sep '26
NI Nippon India Large Cap Fund - Growth - Direct PlanLarge Cap Fund	534.46	1.04	21,34,592	Sep '26
AB Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	518.88	1.85	20,72,385	Sep '26
NI Nippon India Pharma Fund - Growth - Direct PlanPharma & Health Care	401.50	4.38	16,03,562	Sep '26
FT Franklin India Opportunities Fund - Growth - Direct PlanEquity - Thematic Fund - Other	380.97	3.98	15,21,556	Sep '26
AB Aditya Birla Sun Life Large Cap Fund - Growth - Direct PlanLarge Cap Fund	378.18	1.35	15,10,424	Sep '26
HS HSBC Midcap Fund - Growth - Direct PlanMid Cap Fund	373.69	2.22	14,92,496	Sep '26
MI Mirae Asset Midcap Fund - Growth - Direct PlanMid Cap Fund	358.36	1.83	14,31,251	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-15	Substantial Acquisition of Shares	Inter alia, considered and approved:- i. an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V. ( Mankind Netherlands ), a wholly owned subsidiary of the Company in Netherlands, in one or more tranches, thereby increasing the aggregate investment limit to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn; ii. the acquisition of a majority stake (i.e., 70%) in Armed Cell Therapeutics B.V. ( ACTx ) through Mankind Netherlands. ACTx is a Belgium-incorporated biotechnology company engaged in the development of next-generation chimeric antigen receptor T-cell ( CAR-T ) therapies for cancer. ACTx has a pipeline of next-generation CAR-T assets, with its lead programs targeting non-Hodgkin lymphoma and small cell lung cancer
2026-10-08	Board Meeting	Quarterly Results
2026-07-16	Board Meeting	Quarterly Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Mankind Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

10 members across the board and senior leadership

Hitesh Kumar Jain

Company Secretary & Compliance Officer

—

Ramesh Juneja

Chairman

₹16.17 Cr

Mar '26

Rajeev Juneja

Vice Chairman & Managing Director

₹19.57 Cr

Mar '26

Sheetal Arora

Whole Time Director & Chief Executive Officer

₹8.30 Cr

Mar '26

Satish Kumar Sharma

Whole Time Director

₹1.16 Cr

Mar '26

T P Ostwal

Non Executive Independent Director

₹57.00 L

Mar '26

Vijaya Sampath

Non Executive Independent Woman Director

₹56.00 L

Mar '26

Bharat Anand

Non Executive Independent Director

₹38.00 L

Mar '25

Vivek Kalra

Non Executive Independent Director

₹43.00 L

Mar '26

Anish Vanraj Bafna

Non Executive Independent Director

—

MANKIND Latest News

News

10 of 10 articles

COMPANY16 Oct 2026 · 16:42

Mankind Pharma inks definitive pact to acquire majority stake in Armed Cell Therapeutics

Said investment is part of the company’s long term strategy to build a global innovation-led pharmaceutical business

EQUITY12 Oct 2026 · 15:00

Mankind Pharma informs about conference call

EQUITY2 Sept 2026 · 15:14

Mankind Pharma gains on BSE

The company has sold its 100% stake held in Broadway Hospitality Services

COMPANY1 Sept 2026 · 14:39

Mankind Pharma sells 100% stake in Broadway Hospitality Services

Broadway has ceased to be a wholly owned subsidiary of the company with effect from August 31, 2026

COMPANY20 Aug 2026 · 16:27

Mankind Pharma inks pact with China’s Chongqing Chenan Biopharmaceutical

The latest partnership further reinforces the company’s commitment to expanding its diabetes portfolio and bringing a broader range of treatment options to patients in India

EQUITY19 Aug 2026 · 11:42

Mankind Pharma informs about newspaper advertisements

EQUITY14 Aug 2026 · 12:25

Mankind Pharma surges on incorporating wholly owned subsidiary in Netherlands

The company has incorporated WOS under the name and style of ‘Mankind Pharma (Netherlands) B.V.’

COMPANY14 Aug 2026 · 11:59

Mankind Pharma incorporates wholly owned subsidiary in Netherlands

The company has incorporated WOS under the name and style of ‘Mankind Pharma (Netherlands) B.V.’

COMPANY31 Jul 2026 · 11:40

Mankind Pharma reports 30% rise in Q1 consolidated net profit

Consolidated total income of the company increased by 11.65% to Rs 4,075.59 crore in Q1FY27.

EQUITY10 Jul 2026 · 12:45

Mankind Pharma informs about certificate

MANKIND

₹2,217.00

-2.63%